









Markets
/
Stocks
/
nasdaq-crsp
/

CRISPR Therapeutics AG

CRSP

63.990USD

+2.890+4.73%

Close 10/31, 16:00（ET）Quotes delayed by 15 min

5.66BMarket Cap

LossP/E TTM



CRISPR Therapeutics AG

63.990

+2.890+4.73%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of CRISPR Therapeutics AG

Currency: USD Updated: 2025-10-31

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

CRISPR Therapeutics AG's Score

Industry at a Glance

Industry Ranking

130 / 407

Overall Ranking

234 / 4618

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 30 analysts

Buy

Current Rating

80.724

Target Price

+32.12%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

CRISPR Therapeutics AG Highlights

StrengthsRisks

CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 3014.69% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 37.31M.

Fairly Valued

The company’s latest PE is -11.83, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 73.70M shares, increasing 1.92% quarter-over-quarter.

Held by Catherine Wood

Star Investor Catherine Wood holds 10.18M shares of this stock.

Financial Health

Currency: USD Updated: 2025-10-31

The company's current financial score is 5.56, which is lower than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 892.00K, representing a year-over-year increase of 72.53%, while its net profit experienced a year-over-year increase of 64.98%.

Score

Industry at a Glance

Previous score

5.56

Change



Financials

6.12

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.02

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.57

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

4.98

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.11

Key Metrics

Free cash flow

No Data

CRISPR Therapeutics AG's Company Valuation

Currency: USD Updated: 2025-10-31

The company’s current valuation score is 6.72, which is lower than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -11.83, which is -100.00% below the recent high of 0.00 and -288.53% above the recent low of -45.96.

Score

Industry at a Glance

Previous score

6.72

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 130/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-31

The company’s current earnings forecast score is 7.53, which is lower than the Biotechnology & Medical Research industry's average of 8.01. The average price target for CRISPR Therapeutics AG is 81.00, with a high of 268.00 and a low of 32.00.

Score

Industry at a Glance

Previous score

7.53

Change

Support & Resistance

No Data

Analyst Rating

Based on 30 analysts

Buy

Current Rating

80.724

Target Price

+32.12%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-31

The company’s current price momentum score is 6.79, which is higher than the Biotechnology & Medical Research industry's average of 6.66. Sideways: Currently, the stock price is trading between the resistance level at 74.80 and the support level at 56.86, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.43

Change

0.36

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-2.702

Neutral

RSI(14)

46.526

Neutral

STOCH(KDJ)(9,3,3)

14.674

Oversold

ATR(14)

3.853

Low Volatility

CCI(14)

-94.464

Neutral

Williams %R

76.204

Sell

TRIX(12,20)

0.057

Sell

StochRSI(14)

81.106

Buy

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

63.508

Buy

MA10

66.517

Sell

MA20

68.891

Sell

MA50

62.582

Buy

MA100

58.393

Buy

MA200

49.188

Buy

Institutional Confidence

Currency: USD Updated: 2025-10-31

The company’s current institutional recognition score is 7.00, which is higher than the Biotechnology & Medical Research industry's average of 5.21. The latest institutional shareholding proportion is 81.03%, representing a quarter-over-quarter decrease of 2.22%. The largest institutional shareholder is Catherine Wood, holding a total of 10.18M shares, representing 11.20% of shares outstanding, with 6.50% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

ARK Investment Management LLC

Star Investors

10.18M

+0.17%

Capital International Investors

5.59M

-7.89%

BlackRock Institutional Trust Company, N.A.

5.42M

+124.40%

T. Rowe Price Investment Management, Inc.

3.68M

-3.03%

State Street Investment Management (US)

3.27M

+35.64%

Two Sigma Investments, LP

2.89M

+45.53%

Orbis Investment Management Ltd.

2.76M

+76.88%

UBS Financial Services, Inc.

2.59M

+49.73%

Amova Asset Management Americas, Inc

2.41M

-4.95%

The Vanguard Group, Inc.

Star Investors

2.28M

+30.18%

Risk Assessment

Currency: USD Updated: 2025-10-31

The company’s current risk assessment score is 5.11, which is higher than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 1.87. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.